Certolizumab Pegol Reaches the Fetus Poorly in Late Pregnancy
Pregnancy management in women with chronic inflammatory disease often forces a hard trade-off between maternal control and fetal exposure. CRIB addressed that problem directly by measuring certolizumab pegol in mothers, cord blood, and infants around delivery rather than inferring safety from class effects alone. The central question was whether an Fc-free anti-TNF agent, given late in gestation, crosses the placenta in measurable amounts.
The design was pharmacokinetic and prospective, not a retrospective reassurance exercise. Women were eligible if they were at least 30 weeks pregnant and receiving commercial certolizumab pegol for a locally approved indication, with the last dose administered no more than 35 days before delivery. Blood was collected from the mother, the umbilical cord, and the infant at birth, then again from infants at weeks 4 and 8 after delivery. CZP concentrations were measured using a highly sensitive, drug-specific electrochemiluminescence immunoassay with a lower limit of quantification of 0.032 μg/mL.
The study enrolled 16 women, and all 16 completed the protocol. Maternal levels at delivery remained within the expected therapeutic range, with a median concentration of 24.4 μg/mL and a range of 5.0 to 49.4 μg/mL. In other words, the mothers were not underdosed or left unexposed at the time the fetal samples were obtained. The drug was demonstrably present in maternal circulation when placental transfer would have been most relevant.
Maternal Exposure Was Preserved While Fetal Measurement Stayed Near Zero
Of the 16 infants, 2 were excluded from the per-protocol set: one because birth data were missing and one because the pharmacokinetic data were implausible. Among the remaining 14 infants, 13 had no quantifiable certolizumab pegol at birth. One infant showed a measurable value, but the study’s core message remained the same: fetal exposure was either absent or below the assay’s quantification threshold in nearly every evaluable newborn.
That pattern fits the biology of placental transport. IgG antibodies cross the placenta through Fc-mediated transfer, especially in late gestation, when fetal exposure to monoclonal antibodies can rise substantially. Certolizumab pegol is structurally different from full-length IgG antibodies because it lacks an Fc region. Without that Fc fragment, the molecule has little opportunity to exploit the active placental transport pathway that can deliver other biologics to the fetus. The CRIB data translate that pharmacology into human pregnancy samples rather than relying on theory alone.
One sentence carries most of the bedside weight: fetal blood was largely free of quantifiable drug despite therapeutic maternal levels near delivery.
Why the Assay Design Matters in Pregnancy Pharmacokinetics
The choice of a sensitive and certolizumab-specific assay is central to interpreting these results. Pregnancy pharmacokinetic studies can be misleading when assays cross-react with drug fragments or related biologics, especially near the lower end of concentration ranges. Here, the lower limit of quantification was 0.032 μg/mL, a threshold low enough to detect very small amounts of circulating drug if transfer had occurred in a clinically meaningful fashion. That technical precision strengthens the conclusion that the infant samples were not merely unmeasured; they were genuinely negative or below quantifiable detection.
The sampling schedule also reflects a real clinical question. If a biologic crosses the placenta, the issue is not just neonatal blood at delivery; persistence after birth matters too, because drug present in the infant can influence immune function and alter vaccination planning. CRIB therefore extended collection to weeks 4 and 8 after delivery. Even though the provided body does not include those later concentration results, the study architecture itself shows that investigators were looking beyond the delivery room and into the early neonatal period when residual maternal biologic exposure would still be clinically relevant.
For rheumatologists and maternal-fetal clinicians, this distinction changes counseling. A mother whose inflammatory disease is controlled with certolizumab pegol late in pregnancy may not face the same fetal drug burden seen with Fc-containing monoclonal antibodies. The question shifts from whether treatment is possible to how reliably maternal disease control can be maintained without exposing the fetus to appreciable circulating drug.
What This Means for Women With Chronic Inflammatory Disease
Women with chronic inflammatory disease often need ongoing biologic therapy through pregnancy to avoid flare-related disability, pain, and systemic inflammation. Uncontrolled maternal disease can jeopardize both mother and fetus. A drug that preserves maternal therapeutic exposure while leaving the infant with no quantifiable level at birth addresses a central gap in care: it allows disease suppression without the same placental carryover expected from many antibody-based biologics.
The CRIB cohort is small, and the per-protocol analysis excluded two infants. Its scope is pharmacokinetic rather than clinical-outcome based, so it does not prove long-term neonatal safety by itself. It does, however, provide direct human evidence that certolizumab pegol behaves differently from Fc-containing agents in pregnancy. The data are especially relevant in late gestation, when placental IgG transport is most active and fetal exposure to many monoclonal antibodies rises steeply.
For bedside practice, the message is restrained but important: late pregnancy exposure to certolizumab pegol produced therapeutic maternal concentrations, yet nearly all evaluable infants had no quantifiable drug at birth. In a setting where treatment decisions are often forced by imperfect surrogate data, that is a clinically meaningful pharmacokinetic separation between mother and fetus.
The remaining questions are not trivial. Infant sampling beyond birth, the clinical meaning of any detectable neonatal level, and how these pharmacokinetic findings intersect with real-world infection outcomes still matter for counseling and follow-up. CRIB answers the transfer question with unusual clarity, but it does not replace longitudinal neonatal safety data.